Indian Drug Regulator Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf® (Nafithromycin) for the Treatment of Community – Acquired Bacterial Pneumonia (CABP)
Indian Drug Regulator Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf® (Nafithromycin) for the Treatment of Community – Acquired Bacterial Pneumonia (CABP)
Zaynich™ (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme – drug resistant Gram negative pathogens
